<DOC>
	<DOCNO>NCT01658813</DOCNO>
	<brief_summary>The purpose study determine whether combination 5-Fluorouracil ( 5-FU ) interferon , able stimulate immune system kill cancer cell , help increase tumor shrinkage previously-treated metastatic gastrointestinal , kidney , lung Cancer .</brief_summary>
	<brief_title>5-Fluorouracil Followed Interferon-alfa-2b Previously-treated Metastatic Gastrointestinal , Kidney , Lung Cancer</brief_title>
	<detailed_description>Interferon continuous infusion 5-Fluorouracil ( 5-FU ) regimens show response rate range 0-43 % various cancer . Monthly bolus 5-FU + interferon-alfa-2b undergone formal phase II testing . In small pilot study , 5 consecutive day schedule 5-FU interferon-alfa-2b result limit toxicity diarrhea mucositis . A limited schedule recommend . Therefore , reasonable examine schedule . In current study , 5-FU follow interferon-alfa-2b daily 3 day attempt benefit biochemical immunologic mechanism describe .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients must histologicallyproven , metastatic gastrointestinal , kidney , lung cancer disease progression least two prior systemic therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 estimate survival least 3 month . Patients must felt recovered effect prior therapy , past expect white blood count nadir chemotherapy ( &gt; 2 week agent , &gt; 6 week nitrosoureas mitomycinC ) Patient consent must obtain prior entrance onto study . White blood count &gt; 3500/mm3 ; platelet count least 100,000/mm3 ; hemoglobin &gt; 9.0 gm/dl ; bilirubin , Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) less 3 time upper limit normal ; serum creatinine &lt; 1.8 . Corticosteroids immunosuppressive agent permit course study . Patients must receive corticosteroid immunosuppressive medication least 2 week prior entrance onstudy . Patients elevate temperature &gt; 100.5 degree F , must source occult infection exclude . Women childbearing potential must negative pregnancy test must take adequate precaution prevent pregnancy treatment . Evidence significant cardiovascular disease include history recent ( &lt; 6 month ) myocardial infarction , uncompensated congestive heart failure , primary cardiac arrhythmia ( due electrolyte disorder drug toxicity , example ) beyond occasional PVC 's , angina , cerebrovascular accident . Prior history psychiatric disorder could exacerbate interferon therapy could preclude completion therapy . Pregnancy lactation . History hypersensitivity interferon alfa fluoropyrimidines . History severe debilitate pulmonary disease , chronic obstructive pulmonary disease require continuous oxygen therapy . History autoimmune disease require immunosuppression . Documented inflammatory joint systemic inflammatory disease ( Lupus ) could exacerbate interferon therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metastatic Gastrointestinal</keyword>
	<keyword>Metastatic Kidney</keyword>
	<keyword>Metastatic Lung</keyword>
</DOC>